Aztreonam: clinical and pharmacological characteristics at the present stage | CMAC

Aztreonam: clinical and pharmacological characteristics at the present stage

Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(1):19-25

​ Popov D.A., Zubareva N.A., Parshakov A.A.
10.36488/cmac.2023.1.19-25
aztreonam Enterobacterales Pseudomonas aeruginosa resistance carbapenemases
Section
Antimicrobials
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(1):19-25

Abstract

One of the urgent problems of modern health care is the growing resistance of microorganisms to antibiotics, including carbapenems, which until recently were considered as the drugs of choice in the treatment of life-threatening infections. Enzymatic inactivation of antibiotics, including through the production of carbapenemase, is the main mechanism of resistance in Gram-negative bacteria. The treatment of these infections presents significant difficulties due to the extremely limited arsenal of effective drugs. Aztreonam is currently the first and only monocyclic beta-lactam antibiotic, monobactam, which is used in clinical practice for the treatment of infections caused by gram-negative bacteria. The data obtained in vitro and clinical observations are presented. These results justify the use of the drug in infections caused by a number of «problem» Gram-negative pathogens, including those resistant to carbapenems. Aztreonam has a high potential and should be used to treat patients with nosocomial infections – the focus of its use is Gram-negative bacteria-producers of metallo-beta-lactamases.

Dmitriy A. Popov

A.N. Bakulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russia

Zubareva N.A.

Perm State Medical University named after E.A. Wagner, Perm, Russia

Aleksandr A. Parshakov

Perm State Medical University named after E.A. Wagner, Perm, Russia

  • 1. Kuzmenkov A.Yu., Vinogradova A.G., Trushin I.V., Edelstein M.V., Avramenko A.A., Dekhnich A.V., et al. AMRmap: antibiotic resistance monitoring system in Russia. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2021;23(2):198-204. Russian. DOI: 10.36488/cmac.2021.2.198-20
  • 2. Barchitta M., Maugeri A., La Rosa M.C., La Mastra C., Murolo G., Basile G., et al. Carbapenem consumption and rate of carbapenem-resistant gram-negative bacteria: results from the Sicilian surveillance system. Ann Ig. 2021;33(3):289-296. DOI: 10.7416/ai.2020.2402
  • 3. Beloborodov V.B., Golochapov O.V., Gusarov V.G., Zamyatin M.N., Zubareva N.A., Zyryanov S.K., et al. Diagnostics and antimicrobial therapy of infections caused by polyresistant strains of microorganisms, update 2022 (methodological recommendations). Bulletin of anesthesiology and resuscitation. 2022;19(2):84-114. Russian. DOI: 10.21292/2078-56582020-17-1-52-83
  • 4. Yi J., Kim K.H. Identification and infection control of carbapenem-resistant Enterobacterales in intensive care units. Acute Crit Care. 2021;36(3):175-184. DOI: 10.4266/acc.2021.00409
  • 5. Haji S.H., Aka S.T.H., Ali F.A. Prevalence and characterization of carbapenemase encoding genes in multidrugresistant Gram-negative bacilli. PLoS One. 2021;16(11): e0259005. DOI: 10.1371/journal.pone.0259005
  • 6. Ambler R.P. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289(1036):321-31. DOI: 10.1098/rstb.1980.0049
  • 7. Akeda Y. Current situation of carbapenem-resistant Enterobacteriaceae and Acinetobacter in Japan and Southeast Asia. Microbiol Immunol. 2021;65(6):229237. DOI: 10.1111/1348-0421.12887
  • 8. Mauri C., Maraolo A.E., Di Bella S., Luzzaro F., Principe L. The revival of aztreonam in combination with avibactam against metallo-β-lactamase-producing Gram-negatives: a systematic review of in vitro studies and clinical cases. Antibiotics. 2021;10(8):1012. DOI: 10.3390/antibiotics10081012
  • 9. Asempa T.E., Abdelraouf K., Nicolau D.P. Activity of β-lactam antibiotics against metallo-β-lactamaseproducing Enterobacterales in animal infection models: a current state of affairs. Antimicrob Agents Chemother. 2021;65:e02271-20. DOI: 10.1128/AAC.02271-20
  • 10. Smith P.F., Ballow C.H., Booker B.M., Forrest A., Schentag J. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther. 2001;23:1231-1244. DOI: 10.1016/s01492918(01)80103-x
  • 11. Ramsey C., MacGowan A.P. A review of the pharmacokinetics and pharmacodynamics of aztreonam. J Antimicrob Chemother. 2016;71(10):2704-2712. DOI: 10.1093/jac/dkw231
  • 12. Zhou W., Zhou D., Li J., Al-Huniti N., Xu H. Evaluation of aztreonam dosing regimens in patients with normal and impaired renal function: a population pharmacokinetic modeling and Monte Carlo simulation analysis. J Clin Pharmacol. 2017;57(3):336-344. DOI: 10.1002/jcph.810
  • 13. Sykes R.B., Bonner D.P. Aztreonam: the first monobactam. Am J Med. 1985;78(2A):2-10. DOI: 10.1016/00029343(85)90196-2
  • 14. Neu H.C. Aztreonam: the first monobactam. Med Clin North Am. 1988;72:555. DOI: 10.1016/s00257125(16)30758-1
  • 15. Imada A., Kitano K., Kintaka K., Muroi M., Asai M. Sulfazecin and isosulfazecin, novel i3-lactam antibiotics of bacterial origin. Nature. 1981;289:590. DOI: 10.1038/289590a0
  • 16. Sykes R.B., Cimarusti C.M., Bonner D.P., Bush K., Floyd D.M., Georgopapadakou N.H., et al. Monocyclic β-lactam antibiotics produced by bacteria. Nature 1981;291:489. DOI: 10.1038/291489a0
  • 17. AZACTAM® (Aztreonam 1 g or 2 g Powder for Solution for Injection or Infusion, vial). Summary of Product Characteristics. Uxbridge, UK: Bristol-Myers Squibb Pharmaceuticals Limited. May 21, 2021. Available at: www.medicines.org.uk/emc/search?q=AZACTAM+. Accessed December 16, 2022.
  • 18. Sykes R.B., Bonner D.P. Discovery and development of the monobactams. Rev Infect Dis. 1985;7(Suppl. 5):S579. DOI: 10.1093/clinids/7.supplement_4.s579
  • 19. Bush K. A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gramnegative pathogens. Int J Antimicrob Agents. 2015;46:483493. DOI: 10.1016/j.ijantimicag.2015.08.011
  • 20. Queenan A.M., Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev. 2007;20:440-458. DOI: 10.1128/CMR.00001-07
  • 21. Timsit J.F., Wicky P.H., de Montmollin E. Treatment of severe infections due to metallo-betalactamases Enterobacterales in critically ill patients. Antibiotics (Basel). 2022;11(2):144. DOI: 10.3390/antibiotics11020144
  • 22. Durante-Mangoni E., Andini R., Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943-950. DOI: 10.1016/j.cmi.2019.04.013
  • 23. Livermore D.M., Mushtaq S., Warner M., Zhang J., Maharjan S., Doumith M., Woodford N. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55:390-394. DOI: 10.1128/AAC.00756-10
  • 24. Brooke J.S. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25:2-41. DOI: 10.1128/CMR.00019-11
  • 25. Sader H.S., Duncan L.R., Arends S.J.R., Carvalhaes C.G., Castanheira M. Antimicrobial activity of aztreonamavibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from medical centers worldwide. Antimicrob Agents Chemother. 2020;64(11):e01433-20. DOI: 10.1128/AAC.01433-20
  • 26. Drawz S.M., Taracila M., Caselli E., Prati F., Bonomo R.A. Exploring sequence requirements for C(3)/C(4) carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: insights into plasticity of the AmpC beta-lactamase. Protein Sci. 2011;20:941-958. DOI: 10.1002/pro.612
  • 27. Lister P., Sanders W., Sanders C. Cefepime-aztreonam: a unique double betalactam combination for Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1998;42:1610-1619. DOI: 10.1128/AAC.42.7.1610
  • 28. Maryam L., Khan A.U. Combination of aztreonam and cefotaxime against CTX-M-15 type β-lactamases: a mechanism based effective therapeutic approach. Int J Biol Macromol. 2018;116:1186-1195. DOI: 10.1016/j.ijbiomac.2018.05.153
  • 29. Buonomo A., Nucera E., de Pasquale T., Pecora V., Lombardo C., Sabato V., et al. Tolerability of aztreonam in patients with cell-mediated allergy to β-lactams. Int Arch Allergy Immunol. 2011;155(2):155-159. DOI: 10.1159/000318844
  • 30. Patriarca G., Schiavino D., Lombardo C., Altomonte G., De Cinti M., Buonomo A., Nucera E. Tolerability of aztreonam in patients with IgE-mediated hypersensitivity to betalactams. Int J Immunopathol Pharmacol. 2008;21(2):375379. DOI: 10.1177/039463200802100215
  • 31. Instructions for the medical use of the drug Aznam J. Available at: https://grls.rosminzdrav.ru/. Accessed December 16, 2022. Russian.
  • 32. Norrby S.R. Clinical experience with aztreonam in Europe: a summary of studies in Belgium, England, Finland, Ireland, the Netherlands, Norway, Portugal, and Sweden. Rev Infect Dis. 1985;7(Suppl. 4):S836-9. DOI: 10.1093/clinids/7.supplement_4.s836
  • 33. Mukonin A.A. Aztreonam: pharmacological properties and experience of clinical use of monobactam antibiotic. Pharmateca. 2010;5:63-74. Russian.
  • 34. Tobudic S., Prager I., Kussmann M., Obermüller M., Ursli M., et al. Compatibility of aztreonam in four commercial peritoneal dialysis fluids. Sci Rep. 2020;10:1788. DOI: 10.1038/s41598-020-58391-y
  • 35. McCullough B.J., Wiggins L.E., Richards A., Klinker K., Hiemenz J.W., Wingard J.R. Aztreonam for febrile neutropenia in patients with beta-lactam allergy. Transpl Infect Dis. 2014;16:145-152. DOI: 10.1111/tid.12148
  • 36. Morroni G., Bressan R., Fioriti S., D’Achille G. Mingoia M., Cirioni O., et al. Antimicrobial activity of aztreonam in combination with old and new β-lactamase inhibitors against MBL and ESBL co-producing Gram-negative clinical isolates: possible options for the treatment of complicated infections. Antibiotics. 2021;10:1341. DOI: 10.3390/antibiotics10111341
  • 37. Sreenivasan P., Sharma B., Kaur S., Rana S., Biswal M., Ray P., et al. In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: role of combination drugs in antibiotic resistance era. J Antibiot (Tokyo). 2022;75(8):454-462. DOI: 10.1038/s41429022-00537-3
  • 38. Davido B., Fellous L., Lawrence C., Maxime V., Rottman M., Dinh A. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61:e01008-17. DOI: 10.1128/AAC.01008-17
  • 39. Jayol A., Nordmann P., Poirel L., Dubois V. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73:542-544 DOI: 10.1093/jac/dkx393
  • 40. Falcone M., Tiseo G., Nicastro M., Leonildi A., Vecchione A., Casella C., et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients. Clin Infect Dis. 2021;72:2021-2024. DOI: 10.1093/cid/ciaa1410
  • 41. Shields R.K., Doi Y. Aztreonam combination therapy: an answer to metallo-β-lactamase-producing Gram-negative bacteria? Clin Infect Dis. 2020;71(4):1099-1101. DOI: 10.1093/cid/ciz1159
  • 42. Sader H.S., Huynh H.K., Jones R.N. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gramnegative bacilli. Diagn Microbiol Infect Dis. 2003;47:547550. DOI: 10.1016/s0732-8893(03)00158-5
  • 43. Emeraud C., Escaut L., Boucly A., Fortineau N., Bonnin R.A., Naas T., et al. Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-β-lactamase-producing Gram negative bacteria. Antimicrob Agents Chemother. 2019;63:e00010-19. DOI: org/10.1128/AAC.00010-19
  • 44. Maraki S., Mavromanolaki V.E., Moraitis P., Stafylaki D., Kasimati A., Magkafouraki E., et al. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40(8):1755-1759. DOI: 10.1007/s10096-021-04197-3
  • 45. Dupont H., Marciniak S., Zogheib E., Mammeri H., Friggeri A., Ammenouche N., et al. Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to b-lactams in ICU patients: a pilot study. Anaesth Crit Care Pain Med. 2015;34:141-144. DOI: 10.1016/j.accpm.2015.02.004
  • 46. Yakovlev S.V., Zhuravleva M.V., Protsenko D.N., Beloborodov V.B., Briko N.I., Brusina E.B., et al. The SCAT program (Antimicrobial therapy Control Strategy) in the provision of inpatient medical care. Methodological recommendations. Surgery (supplement to the Consilium Medicum journal). 2017;1:15-51. Russian.
  • 47. Clinicaltrials.gov. A study to determine the efficacy, safety and tolerability of aztreonam-avibactam (ATM-AVI) ± metronidazole (MTZ) versus meropenem (MER) ± colistin (COL) for the treatment of serious infections due to Gram negative bacteria. (REVISIT). NCT03329092. Available at: https://clinicaltrials.gov/ct2/show/NCT03329092. Accessed December 16, 2022.
  • 48. Clinicaltrials.gov. Efficacy, safety, and tolerability of ATMAVI in the treatment of serious infection due to MBL-producing Gram-negative bacteria. NCT03580044. Available at: https://clinicaltrials.gov/ct2/show/NCT03580044. Accessed December 16, 2022.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared